Drug Profile

LM 103

Alternative Names: Autologous tumour infiltrating lymphocytes - Suzhou BlueHorse Therapeutics; LM-103

Latest Information Update: 28 Jun 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Suzhou BlueHorse Therapeutics
Class Antineoplastics; Immunotherapies; T lymphocyte cell therapies; Tumour infiltrating lymphocyte therapies
Mechanism of Action Immunologic cytotoxicity; Lymphocyte replacements

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

28 Jun 2025 No recent reports of development identified for phase-I development in Solid-tumours(Late-stage disease) in China (IV, Infusion)
23 Jan 2024 Phase-0 for Solid tumours (Late-stage disease, Combination therapy) in China (Parenteral) (NCT06697665)
25 Jul 2023 Suzhou BlueHorse Therapeutics plans a phase 0 trial for Solid tumours (Late-stage disease, Second-line therapy or greater) in August 2023 (IV, Infusion) (NCT05971576)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com